IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
Sarepta names Michael Severino CEO, reports Q2 2026 results and pipeline updatesAug 5Quarterly updateSarepta Therapeutics, Inc.